Despite the emerging of RAS blockades, SGLT2 inhibitors and NS-MRAs, current treatment options are limited in their ability to effectively impede kidney disease progression and abate risks of comorbidities and death among patients with DKD. Here, SLC5A2 is linked to diabetic kidney disease.